Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation’s Prostate Cancer Drug Strong In Phase I/II

This article was originally published in The Pink Sheet Daily

Executive Summary

More precise criteria could help MDV3100 win where others failed, CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Several Prostate Cancer Drug Candidates Heading Into Home Stretch

In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010

Several Prostate Cancer Drug Candidates Heading Into Home Stretch

In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010

Several Prostate Cancer Drug Candidates Heading Into Home Stretch

In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010.

Related Content

Topics

UsernamePublicRestriction

Register

PS067950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel